Oramed Pharmaceuticals Inc. (ORMP) stock
ORMPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 12/30
$3.89+0.02 (+0.52%)
Close on Nov 18, 2026Market cap $161.81MP/E 0.9Yield 6.43%
Oramed Pharmaceuticals revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Oramed Pharmaceuticals's revenue for the twelve months ending Dec 31, 2025 was $2.00M. For fiscal 2025 it was $2.00M, up 49.3% from the year before. The highest annual figure on record is $2.71M in fiscal 2020.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $2.00M | +49.3% |
| FY2023 | Dec 31, 2023 | $1.34M | -50.4% |
| FY2021 | Aug 31, 2021 | $2.70M | -0.3% |
| FY2020 | Aug 31, 2020 | $2.71M | +0.3% |
| FY2019 | Aug 31, 2019 | $2.70M | +10.4% |
| FY2018 | Aug 31, 2018 | $2.45M | -0.3% |
| FY2017 | Aug 31, 2017 | $2.46M | +283.2% |
| FY2016 | Aug 31, 2016 | $641.00K | – |
Quarterly revenue
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q4 FY2025CQ4 2025 | Dec 31, 2025 | $0 | – |
| Q3 FY2025CQ3 2025 | Sep 30, 2025 | $0 | – |
| Q2 FY2025CQ2 2025 | Jun 30, 2025 | $0 | -100.0% |
| Q1 FY2025CQ1 2025 | Mar 31, 2025 | $2.00M | +200.3% |
| Q4 FY2023CQ4 2023 | Dec 31, 2023 | $0 | -100.0% |
| Q3 FY2023CQ3 2023 | Sep 30, 2023 | $0 | -100.0% |
| Q2 FY2023CQ2 2023 | Jun 30, 2023 | $674.00K | +1.4% |
| Q1 FY2023CQ1 2023 | Mar 31, 2023 | $666.00K | -1.2% |
| Q4 FY2021CQ3 2021 | Aug 31, 2021 | $683.00K | +0.3% |
| Q3 FY2021CQ2 2021 | May 31, 2021 | $681.00K | 0.0% |
| Q2 FY2021CQ1 2021 | Feb 28, 2021 | $665.00K | -1.3% |
| Q1 FY2021CQ4 2020 | Nov 30, 2020 | $674.00K | 0.0% |
| Q4 FY2020CQ3 2020 | Aug 31, 2020 | $681.00K | 0.0% |
| Q3 FY2020CQ2 2020 | May 31, 2020 | $681.00K | -0.1% |
| Q2 FY2020CQ1 2020 | Feb 29, 2020 | $674.00K | +9.2% |
| Q1 FY2020CQ4 2019 | Nov 30, 2019 | $674.00K | +9.2% |
| Q4 FY2019CQ3 2019 | Aug 31, 2019 | $681.00K | +12.7% |
| Q3 FY2019CQ2 2019 | May 31, 2019 | $682.00K | +11.6% |
| Q4 FY2018CQ3 2018 | Aug 31, 2018 | $617.00K | -0.2% |
| Q3 FY2018CQ2 2018 | May 31, 2018 | $617.00K | 0.0% |
| Q2 FY2018CQ1 2018 | Feb 28, 2018 | $604.00K | -1.1% |
| Q1 FY2018CQ4 2017 | Nov 30, 2017 | $611.00K | +0.2% |
| Q4 FY2017CQ3 2017 | Aug 31, 2017 | $618.00K | -33.5% |
| Q3 FY2017CQ2 2017 | May 31, 2017 | $617.00K | – |
| Q2 FY2017CQ1 2017 | Feb 28, 2017 | $611.00K | +388.8% |
| Q1 FY2017CQ4 2016 | Nov 30, 2016 | $610.00K | – |
| Q4 FY2016CQ3 2016 | Aug 31, 2016 | $929.00K | – |
| Q3 FY2016CQ2 2016 | May 31, 2016 | -$163.00K | – |
| Q2 FY2016CQ1 2016 | Feb 29, 2016 | $125.00K | – |
See a number that looks wrong?